TPI provides its latest research note on Microsaic Systems plc (MSYS.L) and DeepVerge plc

Further to Microsaic entering a non-binding Heads of Terms (‘HoT’) with Deepverge (‘the Group’) on 15 February 2021 the two companies have, as expected, today formally announced their signing of a three-year full technical and commercial agreement (the ‘Agreement’).

Under this Agreement, Microsaic will supply regulatory approved, CE Mark, miniaturised mass spectrometry (‘MS’) equipment and services on a non-exclusive basis across Deepverge’s global sales, marketing and distribution channels, delivering portable solutions for environmental contamination detection and healthcare diagnostic evaluation of samples.

For its part, Deepverge will introduce Artificial Intelligence (‘AI’) data analytics into Microsaic’s existing MS data capture capabilities to fast track the Microtox® BT breathalyser with the ambition of delivering a Point of Care (‘POC’) solution direct to the GP’s clinic. By being able to offer such a unique, integrated ‘Lab-to-Sample’ laboratory solution along with POC diagnostic tests, the two Boards consider their products jointly have transformative potential in markets for both environmental detection and healthcare evaluation.

Read More

We would draw your attention to the various disclaimers in the document both at the beginning and at the end of the note. Retail clients (as defined by the rules of the FCA) must not rely on the research document. In particular you should note that the research document is a non-independent marketing communication. The analyst who has prepared the research is aware that TPI provides research to Microsaic Systems plc and DeepVerge plc. Accordingly the research has not been prepared in accordance with legal requirements designed to promote the independence of investment research and is not subject to any prohibitions on dealing ahead of its dissemination.

The information in the document is published solely for information purposes and is not to be construed as a solicitation or an offer to buy or sell any securities or related financial instruments. The material contained in the document is general information intended for recipients who understand the risks associated with equity investment in smaller companies. It does not constitute a personal recommendation as defined by the FCA or take into account the particular investment objectives, financial situation or needs of individual investors nor provide any indication as to whether an investment, a course of action or the associated risks are suitable for the recipient.

Copyright © 2021 Turner Pope Investments (TPI) Limited, all rights reserved.

Linking Shareholders and Executives :Share Talk

If anyone reads this article found it useful, helpful? Then please subscribe or follow SHARE TALK on our Twitter page for future updates. Terms of Website Use All information is provided on an as-is basis. Where we allow Bloggers to publish articles on our platform please note these are not our opinions or views and we have no affiliation with the companies mentioned

Weekly Newsletter

Sign up to receive exclusive stock market content in your inbox, once a week.

We don’t spam! Read our privacy policy for more info.